Edition:
India

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.90USD
17 May 2019
Change (% chg)

$0.06 (+3.26%)
Prev Close
$1.84
Open
$1.84
Day's High
$1.92
Day's Low
$1.83
Volume
27,979
Avg. Vol
62,714
52-wk High
$5.10
52-wk Low
$1.83

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $90.14
Shares Outstanding(Mil.): 47.44
Dividend: --
Yield (%): --

Financials

  ADMP.OQ Industry Sector
P/E (TTM): -- 54.03 55.51
EPS (TTM): -0.96 -- --
ROI: -103.73 11.89 11.59
ROE: -110.00 13.19 16.33

Swiss stocks - Factors to watch on Dec. 7

ZURICH/BERLIN, Dec 7 The Swiss blue-chip SMI was seen opening 1.2 percent higher at 8,765 points on Friday, according to premarket indications by bank Julius Baer .

07 Dec 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

07 Dec 2018

Earnings vs. Estimates